GSK Share PerformanceMore
|52 week high||1,745.5 11/10/16|
|52 week low||1,446.5 06/12/16|
|52 week change||-190.5 (-11.34%)|
|4 week volume||162,219,703 23/07/17|
Latest News« previous» nextMore
17/08/2017 - 13:03 Interactive Investor
This FTSE 250 pharma has seen half its value wiped off in just five months. But Graeme Evans finds one positive analyst ...
10/08/2017 - 16:43 RNS
RNS Number: 7095N GlaxoSmithKline PLC 10 August 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participa...
10/08/2017 - 10:50 RNS
RNS Number: 6530N GlaxoSmithKline PLC 10 August 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mrs V A Whyte b) Position/status SVP & Company Secretary c) Initial notification/ amendment Initial Notification 2. Details of the issuer, emission allowance market parti...
09/08/2017 - 12:50 StockMarketWire
Berenberg today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1835p...
07/08/2017 - 08:30 StockMarketWire
Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to...
04/08/2017 - 09:06 RNS
RNS Number: 1341N GlaxoSmithKline PLC 04 August 2017 Publication of Base Prospectus The following base prospectus dated 3 August 2017 has been approved by the UK Listing Authority and is available for viewing: GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. 15,000,000,000 Euro Medium Term Note Programme Copies of the base pro...
01/08/2017 - 11:02 RNS
RNS Number: 7419M GlaxoSmithKline PLC 01 August 2017 GlaxoSmithKline plc Total Voting Rights and Capital In conformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital as at 31 July 2017 consisted of 5,371,684,285 ordinary shares of 25 pence each...
28/07/2017 - 16:19 Interactive Investor
This FTSE 250 drug-maker went in the opposite direction to AstraZeneca this week and now one analyst is tipping it up to ...
|Dividend yield||5.369 %|
Latest discussion posts More
“""However, reinvigorating pharma R&D will not be a quick fix""" Makes you wonder why there has been no invigoration of the pharma business over the last years then? Getting ...”▼
“Earnings per share growth at GlaxoSmithKline (GSK) will be limited over the next three years, predicts Deutsche Bank, as the pharma giant invests to improve its research and ...”▼
“Shire announced their Q2 results just now and they were pretty ...”▼
Codes & Symbols
|Symbols||GSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK|